超声IOTA-ADNEX模型与MRI ADNEX MR评分诊断高危卵巢癌的前瞻性研究
该前瞻性单中心研究纳入342例一线超声怀疑附件恶性转诊患者,头对头比较超声IOTA-ADNEX模型与MRI ADNEX MR评分鉴别良恶性的诊断效能,主要指标为AUC。IOTA-ADNEX的AUC为0.96(95%CI 0.94-0.98),ADNEX MR为0.93(95%CI 0.91-0.96),两者诊断准确性相当,均可作为二线评估工具。
要点
- IOTA-ADNEX模型AUC 0.96,ADNEX MR评分AUC 0.93,两者诊断效能相当
- 超声与MRI在关键形态学特征上一致性中等至较高(κ=0.46-0.75)
- IOTA-ADNEX在鉴别交界性肿瘤与I期浸润癌时AUC降至0.71
核心结论
- IOTA-ADNEX模型与ADNEX MR评分系统在鉴别附件良恶性方面诊断准确性相当。
- 按病变形态分层后结果一致,两者均可视资源用于一线超声评估为恶性风险的二线检查。
研究设计与样本
- 前瞻性、单中心诊断准确性研究,头对头比较设计。
- 纳入2021年5月至2022年12月丹麦奥胡斯大学医院因一线影像怀疑附件恶性转诊的患者342例(分析342个病灶)。
- 参考标准为原发附件肿块的组织病理学诊断,少数病例采用临床随访。
- 超声检查者与放射科医师对彼此结果及参考标准设盲。
主要发现
- 队列中78.1%为绝经后,恶性患病率58.8%。
- IOTA-ADNEX模型(含或不含CA 125)鉴别良恶性的AUC为0.96(95%CI 0.94-0.98),ADNEX MR为0.93(95%CI 0.91-0.96)。
- 超声与MRI在关键形态学特征上一致性中等至较高(κ=0.46-0.75),病灶大小测量一致性良好至优秀(ICC=0.78-0.92)。
- IOTA-ADNEX模型校准良好,鉴别肿瘤亚型的多分类能力总体较高,但鉴别交界性肿瘤与I期浸润癌时AUC为0.71(95%CI 0.56-0.82)。
关键数值与推荐
- IOTA-ADNEX模型AUC 0.96(95%CI 0.94-0.98),ADNEX MR评分AUC 0.93(95%CI 0.91-0.96)。
- 形态学特征一致性κ=0.46-0.75,病灶大小ICC=0.78-0.92。
- 交界性肿瘤与I期浸润癌鉴别AUC 0.71(95%CI 0.56-0.82)。
临床怎么用
- 一线超声评估为恶性风险的附件肿块,可选择IOTA-ADNEX模型或ADNEX MR评分作为二线评估。
- 具体选择可依据各中心资源条件决定。
- 两者在鉴别交界性肿瘤与I期浸润癌时效能均有限,需结合临床综合判断。
局限性
- 单中心研究,外推性可能受限。
- 恶性患病率较高(58.8%),可能影响诊断准确性估计。
- 部分病例参考标准为临床随访而非组织病理学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To systematically validate and compare ultrasonography, using the ultrasound-based International Ovarian Tumor Analysis - Assessment of Different NEoplasias in the adneXa (IOTA-ADNEX) model, with magnetic resonance imaging (MRI), using the MRI-based ADNEX MR scoring system, as second-line imaging modalities for estimating the risk of adnexal malignancy in patients identified as being at risk of malignancy on first-line ultrasound examination. METHODS: This was a prospective, single-center diagnostic accuracy study designed as a head-to-head comparison. All patients referred to a tertiary referral center at Aarhus University Hospital, Aarhus, Denmark, for suspected adnexal malignancy on first-line imaging between May 2021 and December 2022 were offered second-line diagnostic testing. This comprised both a systematic expert ultrasound examination, including IOTA-ADNEX risk estimation, and a systematic MRI scan with ADNEX MR scores assigned by expert radiologists. The imaging assessments were performed prospectively, with ultrasound examiners and radiologists blinded to the results of other imaging modalities and to the reference standard (tumor outcome). The reference standard was a histopathological diagnosis of the primary adnexal mass or, in a small number of cases, clinical follow-up. Borderline tumors, invasive adnexal malignancy and metastases to the adnexa were grouped as malignancies. Diagnostic performance of the IOTA-ADNEX model, ADNEX MR scoring system and CA 125 for predicting malignancy was evaluated using the area under the receiver-operating-characteristics curve (AUC), and AUCs were compared using DeLong's test. Diagnostic metrics were estimated at clinically relevant cut-offs and scores. Agreement between modalities was assessed for the identification of morphological features and overall risk estimation using Cohen's kappa statistics, intraclass correlation coefficients (ICC) and Bland-Altman plots. For the IOTA-ADNEX model, calibration and the ability to discriminate between tumor subtypes were evaluated. RESULTS: The included cohort comprised 342 patients (342 lesions analyzed). In the final cohort, 78.1% of patients were postmenopausal and the overall prevalence of malignancy was 58.8%. The AUC for distinguishing patients with benign tumors from those with malignant tumors was 0.96 (95% CI, 0.94-0.98) for the IOTA-ADNEX model (with or without CA 125) compared with an AUC of 0.93 (95% CI, 0.91-0.96) for ADNEX MR. Agreement between ultrasound and MRI ranged from moderate to substantial for key morphological features (κ = 0.46-0.75) and from good to excellent for lesion-size measurements (ICC = 0.78-0.92). The IOTA-ADNEX model performed similarly to the ADNEX MR scoring system regardless of lesion morphology or size. The IOTA-ADNEX model had good calibration. Furthermore, its multinomial discriminative ability between tumor subtypes was generally high, although performance was reduced when distinguishing borderline tumors from Stage-I invasive malignancy (AUC, 0.71 (95% CI, 0.56-0.82)). CONCLUSIONS: The IOTA-ADNEX model and ADNEX MR scoring system demonstrated comparable diagnostic accuracy for differentiating benign from malignant adnexal masses in this study. Results appeared to be consistent when stratified by lesion morphology. Both modalities may be used for second-line assessment of masses deemed at risk of malignancy in the first-line ultrasound examination, depending on resources in specific centers. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Dueholm Hjorth IM, Ledger A, Møller C, et al. Ultrasonography (IOTA-ADNEX) vs magnetic resonance imaging (ADNEX MR) for diagnosing ovarian cancer in high-risk patients: a prospective study. Ultrasound Obstet Gynecol. 2026. PMID: 42954917. doi:10.1002/uog.70368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。